This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pharma Clinical Trial Services: World Market 2013-2023

NextGen Sciences

Nexus Oncology

NHS Research Scotland (NRS)



Ontario Teachers' Pension Plan

Oxford Cancer Biomarkers

Oxford Gene Technology (OGT)

Oxford Outcomes (part of ICON)

Pacific Biomarkers

Paragon Biomedical (part of Clinipace Worldwide)

Paramax International (part of RPS)

Parexel International

Perceptive Informatics (part of Parexel)

PFC Pharma Focus (part of Clinipace Worldwide)


Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceuticals and Medical Devices Agency (PMDA) [ Japan]

PharmaNet Development Group (part of inVentiv Health)


PRA International

Prana Biotechnology

PriceSpective (part of ICON)

Prodia Clinical Laboratory

Proteome Sciences

ProTrials Research

Psychmed (part of The Cognition Group)

QED Clinical Services


Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)

ReSearch Pharmaceutical Services (RPS)

Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)



Shanghai Clinical Research Center



State Food and Drug Administration (SFDA) [China]

Sugi Medical Co (part of CMIC)

Taijitu Biologics


The Carlyle Group

The Cognition Group

Theorem Clinical Research

Theradex Systems

Therapeutic Goods Administration (TGA) [ Australia]

Therapharm Recherches (part of RPS)

Thomas H. Lee Partners

Tigermed Consulting

Timaq Medical Imaging (part of ICON)

Trident Clinical Research (part of INC Research)


Veeda Clinical Research

Vigiun (part of Chiltern International)


Warburg Pincus

West Coast Clinical Trials (WCCT)

World Health Organization (WHO)

Worldwide Clinical Research

WuXi AppTec

WuXi PharmaTech

To order this report: Drug_Discovery_and_Development Industry: Pharma Clinical Trial Services: World Market 2013-2023

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001


SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
13 of 13

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%
YHOO $36.59 -0.97%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs